ARCA Biopharma, Inc. has entered into an Agreement and Plan of Merger and Reorganization with Oruka Therapeutics, Inc., in a transaction intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended. The merger will result in Oruka becoming a wholly-owned subsidiary of ARCA.